-
Mashup Score: 0Kidney Disease Surveillance System - 2 month(s) ago
Centers for Disease Control and Prevention (CDC) : CKD Surveillance
Source: nccd.cdc.govCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 0Kidney Disease Surveillance System - 6 month(s) ago
Centers for Disease Control and Prevention (CDC) : CKD Surveillance
Source: nccd.cdc.govCategories: General Medicine News, EndocrinologyTweet-
Come to @ASNKidney #KidneyWeek 2023 in Philadelphia, PA! Check us out at Booth no. 2519 to learn about CDC’s surveillance system that tracks trends in kidney disease and its risk factors in the US. Learn more: https://t.co/NDZ9qhvokr https://t.co/2gJKq38Tkt
-
-
Mashup Score: 0Kidney Disease Surveillance System - 6 month(s) ago
Centers for Disease Control and Prevention (CDC) : CKD Surveillance
Source: nccd.cdc.govCategories: General Medicine News, EndocrinologyTweet-
Come to @ASNKidney #KidneyWeek 2023 in Philadelphia, PA! Check us out at Booth no. 2519 to learn about CDC’s surveillance system that tracks trends in kidney disease and its risk factors in the US. Learn more: https://t.co/NDZ9qhvokr https://t.co/2gJKq38Tkt
-
-
Mashup Score: 2ASN Kidney Week - 2 year(s) ago
Join 10,000 plus professionals to advance the work of kidney medicine worldwide at Kidney Week 2022.
Source: ASN Kidney WeekCategories: Latest Headlines, NephrologyTweet-
Kristina Bryant, MD of University of Louisville @uofl highlights CJASN feature article by @PD_Perls during “Immunity-Friend-and-Foe-in-People-on-Dialysis” session at #KidneyWeek 2022 https://t.co/dMxEZ5Oq4G @UofLMedicine https://t.co/jTwtjq6C2J
-
-
Mashup Score: 23American Society of Nephrology | Kidney Week - - 2 year(s) ago
Program session details for Kidney Week 2022.
Source: www.asn-online.orgCategories: Healthcare Professionals, Latest HeadlinesTweet-
I look forward to delivering keynote remarks "Preventing the Next Pandemic" to the American Society of Nephrology @ASNKidney meetings #KidneyWeek in the first week of November https://t.co/cU3Z8a35mj
-
-
Mashup Score: 0Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved - 2 year(s) ago
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
CKD had no impact on the efficacy or safety of the SGLT2 inhibitor empagliflozin for patients with HFpEF in the EMPEROR-Preserved trial. https://t.co/drZJNypWAN #KidneyWeek https://t.co/KacaKoIc0K
-
-
Mashup Score: 2Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved - 2 year(s) ago
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
CKD had no impact on the efficacy or safety of the SGLT2 inhibitor empagliflozin for patients with HFpEF in the EMPEROR-Preserved trial. https://t.co/WyJOXqkvYn #KidneyWeek https://t.co/e62suYxJqz
-
-
Mashup Score: 0ADVOCATE: Avacopan shows renal benefits in ANCA vasculitis - 3 year(s) ago
A subanalysis of renal effects in the phase 3 ADVOCATE trial found that avacopan improved estimated glomerular filtration rate best among patients with moderate to severe renal disease.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
Treatment of ANCA–associated vasculitis and renal disease with oral C5a receptor inhibitor avacopan provides significant recovery of kidney function, compared with prednisone. https://t.co/t4Mu4Vi6xg #KidneyWeek https://t.co/DZh4uoIqC4
-
-
Mashup Score: 1
“What’s out there [for daprodustat] seems very encouraging,” according to a nephrologist.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
A new trial with over 6K people showed that daily treatment with oral daprodustat was noninferior to standard ESAs for both increasing hemoglobin levels and for CVD safety in patients with CKD. https://t.co/oUy3FyjsZ3 #KidneyWeek https://t.co/dJ7kGTk2Ii
-
-
Mashup Score: 4Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved - 3 year(s) ago
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
CKD had no impact on the efficacy or safety of the SGLT2 inhibitor empagliflozin for patients with HFpEF in the EMPEROR-Preserved trial. https://t.co/YAKyQgbEK9 #KidneyWeek https://t.co/Y8Ngg1sgyO
-
Come to @ASNKidney #KidneyWeek 2023 in Philadelphia, PA! Check us out at Booth no. 2519 to learn about CDC’s surveillance system that tracks trends in kidney disease and its risk factors in the US. Learn more: https://t.co/NDZ9qhvokr https://t.co/2gJKq38Tkt